Insights On Trial Design

  1. Genomic Based Solutions For Your Immuno-oncology Drug Development Needs

    Learn how genomics-based biomarker approaches can empower the success of your immuno-oncology clinical development programs by implementing a tailored biomarker strategy.

  2. The Benefits Of Blinding of Investigational Medicinal Products (IMPs)

    How blinding benefits both the patient and the investigator and drug encapsulation is an effective blinding method.

  3. Integrating Third-Party Lab Management To Streamline Clinical Development

    Real world experiences, pitfalls and best practices that can improve the efficiency of clinical development when centralizing and managing third party vendors.

  4. Clinical Trials Laboratories In The Immuno-Oncology Setting

    The development of immuno-oncology (I/O) medicines offer a new era of treatment options for physicians and patients. However, the level of sophistication required for biomarker selection, trial design, technology implementation, testing, and commercialization planning is unprecedented. Learn more about how clinical trial laboratories are utilizing multiple technologies and solutions to support immuno-oncology clinical development.

  5. Using Gene Signature Methodologies To Strengthen Immuno-Oncology Trials

    Cutting edge genomics technologies to power and enhance immuno-oncology (IO) trials where reporting transcriptional response pairs a person to therapy without multiple biopsies.

  6. Microsatellite Instability Assay For Response To Immunotherapy

    MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens.

  7. Immune Landscape Signatures For Characterization Of Tumor Microenvironment And Response To Therapy

    Gene expression and analysis for detection of 11 Immune Landscape Signatures.

  8. A Proactive Approach To Ebola Vaccine Development

    Best practices for rapid test development and regulatory approvals.

  9. Fighting Cancer: Biomarkers For Immuno-Oncology Clinical Trials

    Using anatomic pathology for biomarker development in clinical trials can help predict and assess how a patient will respond to immuno-oncology therapies

  10. Minimal Residual Disease: Finding The Right Test For The New Definition Of Remission

    Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.